BACKGROUND: The skeletal phenotype of mucopolysaccharidosis VI (MPS VI) is characterized by short stature and growth failure. OBJECTIVE: The purpose of this study was to construct reference growth curves for MPS VI patients with rapidly and slowly progressive disease. METHODS: We pooled cross-sectional and longitudinal height for age data from galsulfase (Naglazyme(®), BioMarin Pharmaceutical Inc.), treatment naïve patients (n = 269) who participated in various MPS VI studies, including galsulfase clinical trials and their extension programs, the MPS VI clinical surveillance program (CSP), and the MPS VI survey and resurvey studies, to construct growth charts for the MPS VI population. There were 229 patients included in this study, of which data from 207 patients ≤25 years of age with 513 height measurements were used for constructing reference growth curves. RESULTS: Height for age growth curves for the 5th, 10th, 25th, 50th, 75th, 90th, and 95th percentiles were constructed for patients with rapidly and slowly progressing disease defined by the pre-enzyme replacement therapy (ERT) uGAG levels of > or ≤200 μg/mg creatinine. The mean (SD) pre-ERT uGAG levels were 481.0 (218.6) and 97.8 (56.3) μg/mg creatinine for the patients ≤25 years of age with rapidly (n = 131) and slowly (n = 76) progressing MPS VI disease, respectively. The median growth curves for patients with ≤ and >200 μg/mg creatinine were above and below the median (50th percentile) growth curve for the entire MPS VI population. CONCLUSION: MPS VI growth charts have been developed to assist in the clinical management of MPS VI patients.
BACKGROUND: The skeletal phenotype of mucopolysaccharidosis VI (MPS VI) is characterized by short stature and growth failure. OBJECTIVE: The purpose of this study was to construct reference growth curves for MPS VIpatients with rapidly and slowly progressive disease. METHODS: We pooled cross-sectional and longitudinal height for age data from galsulfase (Naglazyme(®), BioMarin Pharmaceutical Inc.), treatment naïve patients (n = 269) who participated in various MPS VI studies, including galsulfase clinical trials and their extension programs, the MPS VI clinical surveillance program (CSP), and the MPS VI survey and resurvey studies, to construct growth charts for the MPS VI population. There were 229 patients included in this study, of which data from 207 patients ≤25 years of age with 513 height measurements were used for constructing reference growth curves. RESULTS: Height for age growth curves for the 5th, 10th, 25th, 50th, 75th, 90th, and 95th percentiles were constructed for patients with rapidly and slowly progressing disease defined by the pre-enzyme replacement therapy (ERT) uGAG levels of > or ≤200 μg/mg creatinine. The mean (SD) pre-ERT uGAG levels were 481.0 (218.6) and 97.8 (56.3) μg/mg creatinine for the patients ≤25 years of age with rapidly (n = 131) and slowly (n = 76) progressing MPS VI disease, respectively. The median growth curves for patients with ≤ and >200 μg/mg creatinine were above and below the median (50th percentile) growth curve for the entire MPS VI population. CONCLUSION:MPS VI growth charts have been developed to assist in the clinical management of MPS VIpatients.
Authors: Paul Harmatz; David Ketteridge; Roberto Giugliani; Natalie Guffon; Elisa Leão Teles; M Clara Sá Miranda; Zi-Fan Yu; Stuart J Swiedler; John J Hopwood Journal: Pediatrics Date: 2005-06 Impact factor: 7.124
Authors: M P Gallegos-Arreola; M V Machorro-Lazo; S E Flores-Martínez; G M Zúñiga-González; L E Figuera; A González-Noriega; J Sánchez-Corona Journal: Arch Med Res Date: 2000 Sep-Oct Impact factor: 2.235
Authors: Calogera M Simonaro; Yi Ge; Efrat Eliyahu; Xingxuan He; Karl J Jepsen; Edward H Schuchman Journal: Proc Natl Acad Sci U S A Date: 2009-12-14 Impact factor: 11.205
Authors: Dafne D G Horovitz; Tatiana S P C Magalhães; Angelina Acosta; Erlane M Ribeiro; Liane R Giuliani; Durval B Palhares; Chong A Kim; Ana Carolina de Paula; Marcelo Kerstenestzy; Mara A D Pianovski; Maria Ione F Costa; Francisca C Santos; Ana Maria Martins; Carolina S Aranda; Jordão Correa Neto; Gervina Brady Moreira Holanda; Laércio Cardoso; Carlos A B da Silva; Renata C F Bonatti; Bethania F R Ribeiro; Maria do Carmo S Rodrigues; Juan C Llerena Journal: Mol Genet Metab Date: 2013-03-05 Impact factor: 4.797
Authors: Litsa Karageorgos; Doug A Brooks; Anthony Pollard; Elizabeth L Melville; Leanne K Hein; Peter R Clements; David Ketteridge; Stuart J Swiedler; Michael Beck; Roberto Giugliani; Paul Harmatz; James E Wraith; Nathalie Guffon; Elisa Leão Teles; M Clara Sá Miranda; John J Hopwood Journal: Hum Mutat Date: 2007-09 Impact factor: 4.878
Authors: Delphine Heron; Clarisse Baumann; Jean Jacques Benichou; Jean Paul Harpey; Martine Le Merrer Journal: Eur J Pediatr Date: 2004-06 Impact factor: 3.183
Authors: Nicole M Muschol; Daniel Pape; Kai Kossow; Kurt Ullrich; Laila Arash-Kaps; Julia B Hennermann; Ralf Stücker; Sandra R Breyer Journal: Orphanet J Rare Dis Date: 2019-05-02 Impact factor: 4.123
Authors: Villarreal M Solano; Claudia Yazmín Cossío Mandujano; Carmen Amor Avila-Rejon; Victor Hugo Espin; Hector Paul Quintero Montaño Journal: Mol Genet Metab Rep Date: 2021-05-25
Authors: Simon A Jones; Martin Bialer; Rossella Parini; Ken Martin; Hui Wang; Ke Yang; Adam J Shaywitz; Paul Harmatz Journal: Pediatr Res Date: 2015-09-02 Impact factor: 3.756